Press Releases

Jul 20, 2026 7:55 AM Eastern Daylight Time Immunomic Therapeutics Announces First Patient Dosed in Phase 1 Trial of Cancer Vaccine Candidate ITI-5000 Immunomic Therapeutics Announces First Patient Dosed in

Jun 15, 2026 7:55 AM Eastern Daylight Time ITI Announces PMDA Clearance of CTN for a UNITE®-Based Self-Amplifying RNA Treatment for Japanese Red Cedar Allergy Company to Initiate First-in-Human Phase

Jan 20, 2026 12:03 PM Eastern Standard Time Immunomic Therapeutics Announces FDA Clearance of IND Application for a UNITE®-Based Self-Amplifying RNA Vaccine for Triple-Negative Breast Cancer, to Be Studied Alone

Immunomic Therapeutics Announces Presentation on Self-amplifying RNA vaccines using the UNITE® platform for Triple-negative Breast Cancer at SITC 39th Annual Meeting 2024 Click here for details: https://ow.ly/Se7750U1mUt

Immunomic Therapeutics Reports Positive Results from Its Phase 1 Clinical Trial of ITI-3000 in Patients Diagnosed with Merkel Cell Carcinoma ITI-3000 Demonstrated a Favorable Safety and Tolerability Profile Patients showed

Immunomic Therapeutics Doses First Patient in its Phase 1 Clinical Trial of ITI-1001, a pDNA Vaccine for the Treatment of Glioblastoma Multiforme -Top-Line Data Expected in the Second Quarter of

March 06, 2023 09:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today that

This meeting will feature in-person presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy,

January 04, 2023 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, announced today that

Vaccine exclusively delivered with the PharmaJet Stratis® Needle-free Injection System December 13, 2022 11:00 AM Eastern Standard Time   GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet®, a company that engineers precision delivery systems that overcome

November 08, 2022 08:30 AM Eastern Standard Time   ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the development of LAMP-mediated nucleic acid-based immunotherapy, today announced

October 10, 2022 09:00 AM Eastern Daylight Time   ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today